J&J probes possible Crucell contamination; Hikma aims to use $500M war chest;

@FiercePharma: Drugmakers rack up $1B in small deals. Article | Follow @FiercePharma

> Johnson & Johnson is looking into possible contamination issues at a South Korean drug facility owned by a company that the American healthcare giant is acquiring. Story

> Hikma Pharmaceuticals, which has just bought Baxter International's U.S. drugs unit, has another $500 million war chest to spend on yet more acquisitions. Article

> Canadian health authorities say GlaxoSmithKline is recalling one lot of Emo-Cort skin lotion because of mold contamination and has halted manufacturing of all Emo-Cort products pending an investigation into the cause. News

> Bayer's blood thinner Xarelto matched the standard therapy at preventing blood clots in patients with an irregular heartbeat, results that may determine its success in a market worth as much as $14 billion. Story

> Pfizer topped the list of America's most generous companies in 2009, according to The Chronicle of Philanthropy, with gifts of cash and products valued at $2.3 billion. Report

> Forest Laboratories won approval Teflaro, a treatment for drug-resistant infections that kill tens of thousands of Americans every year. Story

> The FDA has approved Novartis' Afinitor to treat benign brain tumors. Article

> Astellas Pharma cut its full-year profit forecast a second time, saying earnings will be 13 percent less than predicted because of costs relating to its $4 billion takeover of OSI Pharmaceuticals. Report

> Sun Pharmaceutical Industries, India's biggest drugmaker by market value, said second-quarter profit rose 12 percent on higher demand for generic medicines. Report

> Acorda Therapeutics posted its first quarterly profit in at least three years, surprising Wall Street analysts, on continued robust sales of its key drug Ampyra. Item

Biotech News

 @FierceBiotech: Next-gen biotechs pursue 'undruggable' targets. Story | Follow @FierceBiotech

 @JohnCFierce: Had a fine time in Boston talking clinical trials with Sanofi, AstraZeneca, Aveo and Cubist Wednesday. Followed up with finance panel in DC Thursday. | Follow @JohnCFierce

> Roche prepares its counterattack against biosimilars. Story

> Waksal making big development plans for his new biotech venture. Article  

> Biodel shares plunge after FDA demands two new Ph3 trials. Report 

> In bombshell, DOJ reverses stance on gene patents. Item 

> Will Avanir drug OK spark takeover attempt? Story

> GSK inks $231M pact for Ph3 Amicus drug. Article

Biotech IT News

> Site provides trial matches, forum for diabetics. Report

> EDC gets cool reception in the clinic. News

> Ovum analyst sees analytics boost in Oracle CDA 2.0. Item

> HHS counts 200 data breaches. Article

>  FDA creates IT shopping list for makeover. Story 

And Finally... Fifty years after the pill, another birth control revolution may be on the horizon: free contraception for women in the U.S., thanks to the new healthcare law. News